Details of Disease

General Information of Disease (ID: DISWG0OP)

• Disease Name: Tinea pedis
• Synonyms: ringworm of foot; dermatophytosis of foot; dermatophytosis of pes; pes dermatophytosis; athlete's foot
• Disease Class: 1F28: Dermatophytosis
• Definition: Dermatological pruritic lesion in the feet, caused by Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum.
• Disease Hierarchy:
  DISM7JPJ: Dermatophytosis
  DISWG0OP: Tinea pedis
• ICD Code:
  ICD-11: ICD-11: 1F28.2
  ICD-10: ICD-10: B35.3
  Expand ICD-11: '1F28.2
  Expand ICD-10: 'B35.3
• Disease Identifiers:
  MONDO ID: MONDO_0005984
  MESH ID: D014008
  UMLS CUI: C0040259
  MedGen ID: 52759
  SNOMED CT ID: 6020002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 21 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Benzocaine	DMI18HW	Approved	Small molecular drug	[1]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[2]
Butenafine	DMOJ4ZI	Approved	Small molecular drug	[3]
Ciclopirox	DMN5T2A	Approved	Small molecular drug	[4]
Clotrimazole	DMMFCIH	Approved	Small molecular drug	[5]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[6]
Econazole	DMFSWGH	Approved	Small molecular drug	[7]
Griseofulvin	DMK54YG	Approved	Small molecular drug	[8]
Haloprogin	DMH4IVU	Approved	Small molecular drug	[9]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[10]
Ketoconazole	DMPZI3Q	Approved	Small molecular drug	[11]
Luliconazole	DMT73J8	Approved	Small molecular drug	[12]
Miconazole	DMPMYE8	Approved	Small molecular drug	[13]
Naftifine	DMHVBG1	Approved	Small molecular drug	[14]
Nitric Oxide	DM1RBYG	Approved	Small molecular drug	[15]
Oxiconazole	DME7KRM	Approved	Small molecular drug	[16]
Pramoxine	DMZ2LGD	Approved	Small molecular drug	[17]
Salicyclic acid	DM2F8XZ	Approved	Small molecular drug	[18]
Sulconazole	DM2SDUF	Approved	Small molecular drug	[19]
Terbinafine	DMI6HUW	Approved	Small molecular drug	[20]
Tolnaftate	DM28MU7	Approved	Small molecular drug	[21]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DBI-001	DM1EAPF	Phase 2	NA	[22]
IDP-113	DM9D1N5	Phase 2	NA	[23]
SB208	DMCTMOZ	Phase 2	NA	[24]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Benzocaine: Review on a Drug with Unfold Potential. Mini Rev Med Chem. 2020;20(1):3-11.
• [2] Betamethasone FDA Label
• [3] Butenafine FDA Label
• [4] Ciclopirox FDA Label
• [5] Clotrimazole FDA Label
• [6] Cortisone acetate FDA Label
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Griseofulvin FDA Label
• [9] Haloprogin FDA Label
• [10] Hydrocortisone FDA Label
• [11] Ketoconazole FDA Label
• [12] Clinical pipeline report, company report or official report of Valeant pharmaceuticals.
• [13] Miconazole FDA Label
• [14] Naftifine FDA Label
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024215)
• [16] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019828.
• [17] Pramoxine FDA Label
• [18] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [19] Sulconazole FDA Label
• [20] Terbinafine FDA Label
• [21] Tinea pedis: an updated review. Drugs Context. 2023 Jun 29;12:2023-5-1.
• [22] ClinicalTrials.gov (NCT04152226) Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With T. Pedis. U.S. National Institutes of Health.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031269)
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)